Cost-Effectiveness Analysis of Combination Therapy with Peginterferon and Ribavirin for Patients with Chronic Hepatitis C and Associated Diseases in the German Health Care Context

PIN42 Cost-Effectiveness-Analysis of the Combination- Therapy Telaprevir, Peg-IFNα2a and Ribavirin in Patients With Chronic Hepatitis-C in Austria

Value in Health ◽

10.1016/j.jval.2012.08.1109 ◽

2012 ◽

Vol 15 (7) ◽

pp. A392

Author(s):

M. Said ◽

A. Dragosits ◽

E. Walter

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Combination Therapy ◽

Chronic Hepatitis C ◽

Effectiveness Analysis

Cost–effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis

Gastroenterología y Hepatología (English Edition) ◽

10.1016/j.gastre.2016.06.013 ◽

2016 ◽

Vol 39 (7) ◽

pp. 449-457

Author(s):

María Buti ◽

Raquel Domínguez-Hernández ◽

Itziar Oyagüez ◽

Miguel Ángel Casado

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Early Treatment ◽

Advanced Fibrosis ◽

Delayed Treatment ◽

Effectiveness Analysis ◽

Initial Stage ◽

Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan

Journal of Medical Economics ◽

10.3111/13696998.2015.1029492 ◽

2015 ◽

Vol 18 (7) ◽

pp. 502-511 ◽

Cited By ~ 8

Author(s):

Hiroyo Kuwabara ◽

Kirsten Westerhout ◽

Maarten Treur ◽

Karin Cerri ◽

Joerg Mahlich ◽

...

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Genotype 1 ◽

Effectiveness Analysis ◽

Treatment Naïve ◽

PGI18 Treatment of Chronic Hepatitis C Patients with Peginterferon Alfa-2a or Peginterferon Alfa-2b: A Cost-Effectiveness Analysis for the Portuguese NHS Setting

Value in Health ◽

10.1016/j.jval.2011.08.889 ◽

2011 ◽

Vol 14 (7) ◽

pp. A394-A395

Author(s):

J. Areias ◽

T. Branco ◽

F. Calinas ◽

A. Carvalho ◽

G. Macedo ◽

...

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Effectiveness Analysis ◽

Peginterferon Alfa ◽

Chronic Hepatitis C Patients

Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options

Journal of Viral Hepatitis ◽

10.1111/jvh.12278 ◽

2014 ◽

Vol 22 (2) ◽

pp. 175-183 ◽

Cited By ~ 14

Author(s):

P. A. Cortesi ◽

A. Ciaccio ◽

M. Rota ◽

J. K. Lim ◽

S. De Salvia ◽

...

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Treatment Options ◽

Genotype 1 ◽

Effectiveness Analysis ◽

Treatment Naïve

Cost-Effectiveness Analysis Of Daclatasvir With Asunaprevir In Treatment Of Chronic Hepatitis C In The Russian Federation

Value in Health ◽

10.1016/j.jval.2016.09.397 ◽

2016 ◽

Vol 19 (7) ◽

pp. A415

Author(s):

R Yagudina ◽

A Kulikov ◽

VV Babiy

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Russian Federation ◽

Effectiveness Analysis ◽

The Russian Federation

Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response

Liver International ◽

10.1111/j.1478-3231.2008.01736.x ◽

2009 ◽

Vol 29 (1) ◽

pp. 120-125 ◽

Cited By ~ 8

Author(s):

Hidenori Toyoda ◽

Takashi Kumada ◽

Seiki Kiriyama ◽

Yasuhiro Sone ◽

Makoto Tanikawa ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Combination Therapy ◽

Chronic Hepatitis C ◽

Virological Response ◽

Rapid Virological Response ◽

Virus Genotype ◽

Genotype 2 ◽

Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil

Cost Effectiveness and Resource Allocation ◽

10.1186/1478-7547-11-25 ◽

2013 ◽

Vol 11 (1) ◽

pp. 25 ◽

Cited By ~ 8

Author(s):

Fabio MR Barros ◽

Hugo Cheinquer ◽

Carolina T Tsuchiya ◽

Eduardo AV Santos

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

The Public ◽

Effectiveness Analysis ◽

Payer Perspective ◽

Public Payer ◽

Peginterferon Alfa

Cost Effectiveness Analysis of The Use Of Daclatasvir + Asunaprevir in The Treatment of Patients with Chronic Hepatitis C in Peru

Value in Health ◽

10.1016/j.jval.2017.08.2910 ◽

2017 ◽

Vol 20 (9) ◽

pp. A930

Author(s):

C Sanabria ◽

R Roman ◽

D Montano ◽

D Mercado ◽

G Valenzuela ◽

...

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Effectiveness Analysis

PIN8 COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON (ALFA-2B) WITH RIBAVIRIN COMPARED WITH PEGINTERFERON (ALFA-2A) WITH RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C

Value in Health ◽

10.1016/s1098-3015(11)72807-8 ◽

2010 ◽

Vol 13 (7) ◽

pp. A431

Author(s):

VV Omelyanovsky ◽

MV Avksentieva ◽

I Krysanov ◽

O Ivakhnenko

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Effectiveness Analysis ◽

Peginterferon Alfa